Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ICML 2021 | IELSG30: treating primary testicular DLBCL

Annarita Conconi, MD, Ospedale degli Infermi, Biella, Italy, summarizes the 5-year results of the Phase II IELSG30 trial (NCT00945724) assessing R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone), intravenous methotrexate, liposomal cytarabine, and scrotal irradiation in patients with primary diffuse large B-cell lymphoma (DLBCL) of the testis. DLBCL of the testis has a risk of central nervous system (CNS) relapse and treatment resulted in a high progression-free survival (PFS) rate, with no CNS relapses reported. Late relapses remain a problem and PD-L1 inhibitors may prevent late relapses. This interview took place during the 2021 International Conference on Malignant Lymphoma (16-ICML).